Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Altimmune Inc (NQ: ALT )

9.230 -0.410 (-4.25%)
Streaming Delayed Price Updated: 1:19 PM EST, Dec 10, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Altimmune Inc

< Previous 1 2 3 4 5 6 7 8 9 Next >
48 Biggest Movers From Yesterday
Gainers Gaucho Group Holdings, Inc. (NASDAQ: VINO) shares jumped 95.1% to close at $7.98 on Wednesday. Gaucho Group highlighted the launch of its Amazon Storefront. Orphazyme A/S... 
Via Benzinga
Altimmune's Stock Trades In A Double Bottom Pattern: What's Next?
Altimmune Inc. (NASDAQ: ALT) shares traded higher after the company announced data from its ALT-801 Phase 1 Trial in overweight and obese volunteers. The company announced that... 
Via Benzinga
Here's Why Altimmune Stock Is Surging Today
An experimental new weight loss drug produced compelling data in an early stage clinical trial. 
Via The Motley Fool
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers Orphazyme (NASDAQ:ORPH) shares moved upwards by 72.49% to $17.34 during Wednesday's regular session. As of 12:31 EST, Orphazyme's stock is trading at a... 
Via Benzinga
Why Altimmune Shares Are Trading Higher Today
Altimmune (NASDAQ: ALT) shares are trading higher after the company announced interim data from its ALT-801 Phase 1 trial. Weight loss of 5.4% at 6 weeks was achieved, surpassing... 
Via Benzinga
36 Stocks Moving In Wednesday's Mid-Day Session
Gainers Opthea Limited (NASDAQ: OPT) shares surged 50.7% to $13.28. The company recently appointed Mrs. Karen Adams as Vice President of Finance and Company Secretary. Kindred... 
Via Benzinga
The Daily Biotech Pulse: Regeneron COVID-19 Antibody Cocktail Data, FDA Nod For Mallinckrodt, Molecular Partners IPO
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 15) Apellis Pharmaceuticals,... 
Via Benzinga
Exposures COVID-19 Product Safety
Altimmune's ALT-801 Achieves 5.4% Weight Loss Surpassing Pre-Established Target Of 2%
Altimmune Inc (NASDAQ: ALT) announced results from a prespecified 6-week interim analysis of its Phase 1 trial of ALT-801 in healthy, overweight, and obese volunteers. The study... 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers Aethlon Medical (NASDAQ:AEMD) shares moved upwards by 347.96% to $9.9 during Wednesday's regular session. As of 12:30 EST, Aethlon Medical's stock is... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 2, 2021
Upgrades According to Barrington Research, the prior rating for Landec Corp (NASDAQ:LNDC) was changed from Market Perform to Outperform. Landec earned $0.09 in the third... 
Via Benzinga
A Peek Into The Markets: US Stock Futures Mixed Ahead of ADP Report, Fed Minutes
Pre-open movers U.S. stock futures traded mixed in early pre-market trade after the Wall Street closed mixed in the previous session. Investors are awaiting earnings results from... 
Via Benzinga
Topics Economy
Exposures Interest Rates
Altimmune's Intranasal COVID-19 Vaccine Candidate Neutralizes South African Variant, Animal Study Shows
Altimmune Inc (NASDAQ: ALT) has announced new results from a preclinical study of AdCOVID, the company's vaccine candidate. Data demonstrated that the vaccine... 
Via Benzinga
Exposures COVID-19
The Daily Biotech Pulse: Nabriva Jumps On Data, Larimar Wilts After Study Put On Hold, Travere To Delay Regulatory Filing
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 25) ESSA Pharma Inc. (NASDAQ:... 
Via Benzinga
52 Biggest Movers From Yesterday
Gainers Scopus BioPharma Inc. (NASDAQ: SCPS) shares climbed 72% to close at $10.25 on Monday after the company reported the FDA approval of IND application for CpG-STAT3siRNA,... 
Via Benzinga
Exposures Product Safety
Looking Into Altimmune's Return On Capital Employed
During Q1, Altimmune's (NASDAQ:ALT) reported sales totaled $837.52 thousand. Despite a 38.25% in earnings, the company posted a loss of $14.86 million. Altimmune collected $2.31... 
Via Benzinga
ALTIMMUNE INC (ALT) Q1 2021 Earnings Call Transcript
ALT earnings call for the period ending March 31, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Earnings Scheduled For May 17, 2021
Companies Reporting Before The Bell • Hycroft Mining Holding (NASDAQ:HYMC) is estimated to report earnings for its first quarter. • U.S. Well Services (NASDAQ:... 
Via Benzinga
Altimmune Stock Clears Key Benchmark, Hitting 80-Plus RS Rating
On Tuesday, Altimmune stock received a positive adjustment to its Relative Strength Rating, from 78 to 86. The biopharma stock is worth watching. 
Via Investor's Business Daily
Altimmune's Intranasal COVID-19 Vaccine Candidate Shows Sterilizing Immunity After Single Dose
Altimmune Inc (NASDAQ: ALT) has announced positive results from a preclinical study evaluating its intranasal COVID-19 vaccine candidate, AdCOVID, in a SARS-... 
Via Benzinga
Exposures COVID-19
Could AstraZeneca's Nasal COVID Vaccine Development Zap Altimmune's Prospects?
The short answer: It depends. 
Via The Motley Fool
Exposures COVID-19
< Previous 1 2 3 4 5 6 7 8 9 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.